Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152

1.

Personalized prediction of tumor response and cancer progression on prostate needle biopsy.

Donovan MJ, Khan FM, Fernandez G, Mesa-Tejada R, Sapir M, Zubek VB, Powell D, Fogarasi S, Vengrenyuk Y, Teverovskiy M, Segal MR, Karnes RJ, Gaffey TA, Busch C, Haggman M, Hlavcak P, Freedland SJ, Vollmer RT, Albertsen P, Costa J, Cordon-Cardo C.

J Urol. 2009 Jul;182(1):125-32. doi: 10.1016/j.juro.2009.02.135. Epub 2009 May 17.

PMID:
19450827
2.

Factors predicting prostatic biopsy Gleason sum under grading.

Stackhouse DA, Sun L, Schroeck FR, Jayachandran J, Caire AA, Acholo CO, Robertson CN, Albala DM, Polascik TJ, Donatucci CF, Maloney KE, Moul JW.

J Urol. 2009 Jul;182(1):118-22; discussion 123-4. doi: 10.1016/j.juro.2009.02.127. Epub 2009 May 17.

PMID:
19447436
3.

Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy.

Donovan MJ, Hamann S, Clayton M, Khan FM, Sapir M, Bayer-Zubek V, Fernandez G, Mesa-Tejada R, Teverovskiy M, Reuter VE, Scardino PT, Cordon-Cardo C.

J Clin Oncol. 2008 Aug 20;26(24):3923-9. doi: 10.1200/JCO.2007.15.3155.

PMID:
18711180
4.

The independent impact of extended pattern biopsy on prostate cancer stage migration.

Master VA, Chi T, Simko JP, Weinberg V, Carroll PR.

J Urol. 2005 Nov;174(5):1789-93; discussion 1793.

PMID:
16217288
5.

Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy?

Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR.

J Urol. 2001 Jul;166(1):111-5.

PMID:
11435834
6.

Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer.

Walz J, Chun FK, Klein EA, Reuther A, Saad F, Graefen M, Huland H, Karakiewicz PI.

J Urol. 2009 Feb;181(2):601-7; discussion 607-8. doi: 10.1016/j.juro.2008.10.033. Epub 2008 Dec 13.

PMID:
19084864
7.

Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.

Paparel P, Cronin AM, Savage C, Scardino PT, Eastham JA.

Eur Urol. 2009 Feb;55(2):404-10. doi: 10.1016/j.eururo.2008.07.007. Epub 2008 Jul 14.

PMID:
18639970
8.

Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence.

Shikanov S, Song J, Royce C, Al-Ahmadie H, Zorn K, Steinberg G, Zagaja G, Shalhav A, Eggener S.

J Urol. 2009 Jul;182(1):139-44. doi: 10.1016/j.juro.2009.02.139. Epub 2009 May 17.

PMID:
19450829
10.

Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.

Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, Shariat SF.

Eur Urol. 2009 May;55(5):1124-33. doi: 10.1016/j.eururo.2008.06.054. Epub 2008 Jun 23.

PMID:
18585843
11.

Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.

Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC Jr; SEARCH Database Study Group.

J Urol. 2003 Jun;169(6):2136-41.

PMID:
12771735
12.

Percent tumor involvement and risk of biochemical progression after radical prostatectomy.

Rampersaud EN, Sun L, Moul JW, Madden J, Freedland SJ.

J Urol. 2008 Aug;180(2):571-6; discussion 576. doi: 10.1016/j.juro.2008.04.017. Epub 2008 Jun 12.

PMID:
18554662
13.

Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.

Bianco FJ Jr, Scardino PT, Stephenson AJ, Diblasio CJ, Fearn PA, Eastham JA.

Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):448-53.

PMID:
15890586
14.

Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.

Tan N, Lane BR, Li J, Moussa AS, Soriano M, Jones JS.

J Urol. 2008 Oct;180(4):1325-9; discussion 1329. doi: 10.1016/j.juro.2008.06.022. Epub 2008 Aug 15.

PMID:
18707706
15.

Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.

Grossfeld GD, Latini DM, Lubeck DP, Broering JM, Li YP, Mehta SS, Carroll PR.

Urology. 2002 Apr;59(4):560-5.

PMID:
11927314
16.

Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.

Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F.

Urology. 2009 May;73(5):1087-91. doi: 10.1016/j.urology.2008.10.048. Epub 2009 Feb 4.

PMID:
19195695
17.
18.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
19.

Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.

Freedland SJ, Presti JC Jr, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL; SEARCH Database Study Group.

J Urol. 2003 Jun;169(6):2129-35.

PMID:
12771734
20.

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG.

J Urol. 2008 Nov;180(5):1975-8; discussion 1978-9. doi: 10.1016/j.juro.2008.07.060. Epub 2008 Sep 17.

PMID:
18801539

Supplemental Content

Support Center